Biotest Pharmaceuticals Announces Strategic Long-Term Manufacturing, Supply
and License Agreement
BOCA RATON, Fla., Jan. 10, 2013
BOCA RATON, Fla., Jan. 10, 2013 /PRNewswire/ --Biotest Pharmaceuticals Corp.
(BPC), a wholly owned U.S. subsidiary of Biotest AG (Dreieich, Germany), today
announced it has entered into a strategic long-term manufacturing, supply, and
license agreement with ADMA Biologics, Inc. (ADMA).
Under the terms of the agreement, ADMA has agreed to purchase exclusively from
BPC its worldwide requirements of RSV (Respiratory Syncytial Virus) Immune
Globulin manufactured from human plasma containing RSV antibodies. The
initial term of the agreement is for ten years. BPC will receive payment for
manufacturing services provided under the agreement as well as a percentage
royalty on ADMA's product revenues up to a specified maximum. In exchange, BPC
has agreed to provide manufacturing services and granted ADMA a license to use
BPC's proprietary fractionation and purification manufacturing process for
Intravenous Immune Globulin.
"We are very pleased to partner with ADMA on their lead product candidate.
Our ability to provide specialized contract manufacturing services will enable
us to diversify our future revenue sources," stated Jordan Siegel, Chief
Executive Officer of BPC.
About Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation, a wholly owned subsidiary of Biotest AG,
researches, develops and manufactures biotherapeutic products with a
specialization in immunology and hematology. BPC is a leader in the collection
of source plasma and is currently involved in the development of plasma
protein products and various hyperimmune (IG) products. The Company owns and
manages twelve plasmapherisis centers across the United States and
astate-of-the-art manufacturing facility in Boca Raton, Florida. The Company
employs more than 700 people in the U.S.
About Biotest AG
Biotest AG is a provider of pharmaceutical and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development to
worldwide sales, Biotest has specialized primarily in the areas of application
of clinical immunology, hematology and intensive medicine. In its Plasma
Protein segment, Biotest develops and markets immunoglobulins, coagulation
factors and albumins based on human blood plasma. These are used for diseases
of the immune and hematopoietic systems. In the Biotherapeutic segment,
Biotest researches into the clinical development of monoclonal antibodies,
including in the indications of rheumatoid arthritis and cancer of plasma
cells. Biotest has more than 1.600 employees worldwide. The preference shares
of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments. The
forward-looking statements are only valid at the time of publication. Biotest
does not intend to update the forward-looking statements and assumes no
obligation to do so.
Main Number: 561-989-5800
SOURCE Biotest Pharmaceuticals Corporation
Contact: Nina Johnson, +1-561-989-5831, email@example.com
Press spacebar to pause and continue. Press esc to stop.